← Back to list
Gene Expression Testing in the Evaluation of Patients with Stable Ischemic Heart Disease
Effective date
Not stated in the notice
Identified
Jun 20, 2026
Summary
Gene expression testing in the evaluation of patients with stable ischemic heart disease is considered investigational for all indications, including but not limited to prediction of coronary artery disease in stable, nondiabetic patients. CardioDX has closed operations, and the Corus CAD test is no longer available.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.
Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.
What to do
Action · 2 steps
01Billing team: Do not bill gene expression testing for stable ischemic heart disease as a medically necessary service, because the policy considers it investigational for all indications.
02CPT 81493 and CPT 84999 (Unlisted chemistry procedure) are listed as the investigational codes.
Codes mentioned
8149384999
Original notice
Gene Expression Testing in the Evaluation of Patients with Stable Ischemic Heart Disease
bcbsms.com · Always check the source before changing claims.
Related changes
See all Blue Cross & Blue Shield of Mississippi changes →Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, NTRK)MediumNo effective date · Medical PolicyIntracellular Micronutrient AnalysisMediumNo effective date · Medical PolicyLaboratory and Genetic Testing for Use of 5-Fluorouracil in Patients With CancerMediumNo effective date · Medical PolicyGermline Genetic Testing for Familial Cutaneous Malignant Melanoma (CDKN2A, CDK4)MediumNo effective date · Medical PolicyBrowse every Blue Cross & Blue Shield of Mississippi change in the policy list